Quanterix’s Ultrasensitive Simoa™ Technology Forges New Ground With Direct Detection of Genomic DNA in Human Blood and River Water
1/22/2013 9:24:28 AM
More...
|
Quanterix Raises $18.5 Million, Inks Deal With bioMerieux, Inc.
11/16/2012 7:06:53 AM
More...
|
bioMerieux SA and Quanterix Sign Strategic Partnership in Ultrasensitive and Multiplex Immunoassays
11/15/2012 10:40:57 AM
More...
|
Quanterix's Ultrasensitive Simoa™ Technology Demonstrates Equivalence with NAT and 3,000x Improvement in Sensitivity Over Conventional Immunoassays for HIV Detection
10/12/2012 10:51:15 AM
More...
|
Quanterix Issued Key Patent for Simoa™ Technology
8/7/2012 10:09:54 AM
More...
|
Quanterix Appoints Paul Chapman as President and Chief Executive Officer
7/20/2012 9:51:28 AM
More...
|
Quanterix to Collaborate With the Forsyth Institute and to Develop Tuberculosis Test
2/9/2012 2:45:09 PM
More...
|
Quanterix Announces Strategic Investment From IQT
1/5/2012 12:46:55 PM
More...
|
Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
12/22/2011 10:28:14 AM
More...
|
Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
12/1/2011 1:45:15 PM
More...
|
|